Seitz. Stephan S; Hohla. Florian F; Schally. Andrew V AV; Moder. Angelika A; Engel. Joerg B JB; Horn...
A lab study found that a new compound that blocks growth‑hormone‑releasing hormone (GHRH) can stop breast cancer cells from growing, no matter whether they have estrogen receptors or not. The cancer cells actually make their own GHRH, which seems to help them multiply, and the blocker shut this down. This work is still in cell dishes, not in people, and uses a different molecule than the commonly used sermorelin.
Stangelberger. Anton A; Schally. Andrew V AV; Varga. Jozsef L JL; Zarandi. Marta M; Szepeshazi. Karo...
This study tested drugs that block growth‑hormone‑releasing hormone (GHRH) and bombesin signals in mice with aggressive prostate cancer. The blockers slowed tumor growth, especially when used together, and reduced spread to bone and other organs. However, the compounds are antagonists (they block the hormone), not sermorelin, which is a GHRH‑activating peptide, so the results don’t give direct guidance for using sermorelin.
Lamharzi. N N; Schally. A V AV; Koppán. M M; Groot. K K
In a mouse study, a drug that blocks growth hormone‑releasing hormone (called MZ‑5‑156) shrank prostate cancer tumors and cut down a growth‑promoting protein called IGF‑II inside the tumors, but the work was done in animals and used a compound that isn’t the same as the peptide sermorelin.
Pinski. J J; Schally. A V AV; Groot. K K; Halmos. G G; Szepeshazi. K K; Zarandi. M M; Armatis. P P
In mice with human bone cancer cells, a synthetic peptide that blocks the hormone that normally makes the body release growth hormone (called a GH‑RH antagonist) slowed tumor growth and lowered IGF‑I levels, while a hormone that stimulates growth hormone made the tumors grow faster.
Kovacs. M M; Kineman. R D RD; Schally. A V AV; Zarandi. M M; Groot. K K; Frohman. L A LA
In mice engineered to overproduce human GHRH (a hormone that makes the body release growth hormone), two experimental drugs that block GHRH (called MZ-4-71 and MZ-5-156) were able to sharply lower the excess growth hormone and IGF‑1 levels. The effect lasted several hours after a single injection and persisted with repeated dosing, showing that these blockers can effectively dial down an overactive GH system.
The study tested modified versions of the growth hormone‑releasing peptide (like sermorelin) to see if they lasted longer in the blood or were absorbed better. The changes did not make a meaningful difference – half‑life and how much got into the bloodstream stayed about the same as the original peptide.
Chang. Yuanhao Y; Huang. Ruoyu R; Zhai. You Y; Huang. Lijie L; Feng. Yuemei Y; Wang. Di D; Chai. Rui...
A computer‑based study looked at gene data from glioma patients and found that the peptide sermorelin might slow tumor growth and boost immune activity in recurrent brain cancer, but this is only a theoretical finding and not a proven treatment for anyone else.
Thomas. Andreas A; Walpurgis. Katja K; Thevis. Mario M
The paper describes a new lab technique for spotting medium‑size peptides like sermorelin in urine, mainly to catch doping in sports. It’s about how to detect the drug, not how to use it, so it doesn’t give biohackers any practical advice on dosing or benefits.
Muñoz-Moreno. Laura L; Gómez-Calcerrada. M Isabel MI; Arenas. M Isabel MI; Carmena. M Jos&...
The study tested a drug that blocks a hormone receptor (MIA‑690) together with an EGFR blocker (Gefitinib) in prostate‑cancer cells and mice, showing they work better together to slow tumor growth.
Wu. Hsien-Ming HM; Schally. Andrew V AV; Cheng. Jung-Chien JC; Zarandi. Marta M; Varga. Jozsef J; Le...
The study shows that a lab-made drug that blocks growth‑hormone‑releasing hormone can kill endometrial cancer cells in a dish by turning on a cell‑death pathway, but it doesn’t tell you anything you can do at home with sermorelin or other supplements.
Scientists made new versions of a molecule that blocks the hormone that tells the body to release growth hormone. In mice and cell tests, some of these blockers stopped cancer cells from growing and reduced inflammation better than an older version, but the work is still early and only in labs, not in people.
Pozsgai. Eva E; Schally. Andrew V AV; Zarandi. Marta M; Varga. Jozsef L JL; Vidaurre. Irving I; Bell...
The study tested two experimental GHRH‑blocking compounds on brain‑cancer cells and found they killed the cells and slowed tumor growth in mice, but this work is limited to lab and animal models and does not provide any guidance for using sermorelin or related peptides in everyday health or longevity practice.
Stangelberger. Anton A; Schally. Andrew V AV; Zarandi. Marta M; Heinrich. Elmar E; Groot. Kate K; Ha...
In mice with prostate cancer, drugs that block growth‑hormone‑releasing hormone (GHRH) helped standard hormone‑blocking treatments work better and slowed tumor growth, even in cancers that no longer need male hormones.
Jimenez. Joaquin J JJ; DelCanto. Gina M GM; Popovics. Petra P; Perez. Aymee A; Vila Granda. Ailin A;...
Scientists discovered that blocking the growth‑hormone‑releasing hormone (GHRH) receptor can slow the growth of certain leukemia cells in lab tests and in mice, and the same receptor is found in patient leukemia samples.
Muñoz-Moreno. Laura L; Schally. Andrew V AV; Prieto. Juan C JC; Carmena. M José MJ; Bajo....
The study tested three experimental drugs that block growth‑hormone‑releasing‑hormone receptors and found they slowed prostate cancer cell growth and increased cell death in lab dishes, but it doesn’t tell you anything useful for using sermorelin or other health‑boosting peptides in everyday life.
This study looked at a growth‑hormone‑releasing‑hormone (GH‑RH) blocker called MZ‑4‑71 and found it can boost a type of memory in mice, but that boost disappears when certain brain receptors (muscarinic, serotonin‑1/2, and opioid) are blocked. The work doesn’t involve sermorelin (a GH‑RH agonist) and offers no dosing or practical tips for people who take GH‑related peptides.
Ziegler. C G CG; Ullrich. M M; Schally. A V AV; Bergmann. R R; Pietzsch. J J; Gebauer. L L; Gondek....
The study tested several experimental peptide drugs on mouse tumor cells and found they could kill those cells, but the work is purely pre‑clinical, uses mouse models, and doesn’t provide any guidance for human health, longevity, or performance use.
Köster. Frank F; Jin. Li L; Shen. Yuanming Y; Schally. Andrew V AV; Cai. Ren-Zhi RZ; Block. Nor...
Scientists tested a drug that blocks growth‑hormone‑releasing hormone (GHRH) called MIA‑602 and found it shrank endometriosis tissue in mice and slowed cell growth in lab dishes, but this has nothing to do with sermorelin or everyday health hacks.
Muñoz-Moreno. Laura L; Arenas. Maria Isabel MI; Carmena. María J MJ; Schally. Andrew V AV;...
Scientists tested two GHRH‑blocking drugs on prostate cancer cells and saw they slowed cell growth and triggered cell death, but these compounds are experimental cancer treatments and not relevant for everyday health or longevity use.
Klukovits. Anna A; Schally. Andrew V AV; Szalontay. Luca L; Vidaurre. Irving I; Papadia. Andrea A; Z...
The study tested new drugs that block the hormone that normally tells the pituitary to release growth hormone. In lab and mouse models of ovarian cancer, these blockers slowed tumor growth and reduced blood vessel formation, but they were not about using growth‑hormone‑releasing peptides like sermorelin for health or performance.